The role of taxanes in HR+ve/HER2-ve metastatic breast cancer (MBC) patients (pts) from adjuvant to metastatic setting in the clinical practice: Results from GIM13-AMBRA study.

被引：1
作者：
Mustacchi, Giorgio
Cazzaniga, Marina Elena
Romagnoli, Emanuela
Montemurro, Filippo
De laurentiis, Michele
Riccardi, Ferdinando
Turletti, Anna
Beano, Alessandra
De Angelis, Claudia
Graziano, Vincenzo
Livi, Lorenzo
Del Mastro, Lucia
Biganzoli, Laura
Garrone, Ornella
De Placido, Sabina
Marchetti, Paolo
Pronzato, Paolo
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：6
相关论文
共 50 条
[11]   Impact of use of antibody drug conjugates on the prognostic outcome of patients with HR+ve/HER2-ve MBC: Results from a real world dataset. [J].
Dawood, Shaheenah S. ;
Hernandez, Gema ;
Segovia, Alba .
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[12]   Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset [J].
Dawood, S. ;
Hernandez-Ibarburu, G. ;
Segovia, A. .
ANNALS OF ONCOLOGY, 2024, 35 :S396-S397
[13]   Choice of treatment and adherence to international ESO-ESMO (ABC) guidelines in HR+/HER2-ve metastatic breast cancer (MBC) patients (pts). [J].
Cazzaniga, Marina Elena ;
Mustacchi, Giorgio ;
Romagnoli, Emanuela ;
Montemurro, Filippo ;
Caporello, Paola ;
De laurentiis, Michele ;
Riccardi, Ferdinando ;
Turletti, Anna ;
De Angelis, Claudia ;
Graziano, Vincenzo ;
Livi, Lorenzo ;
Del Mastro, Lucia ;
Beano, Alessandra ;
Garrone, Ornella ;
Biganzoli, Laura ;
Pronzato, Paolo ;
De Placido, Sabino .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[14]   Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study. [J].
Mustacchi, Giorgio ;
Pronzato, Paolo ;
Arpino, Grazia ;
D'Alonzo, Alessia ;
Piezzo, Michela ;
Natoli, Clara ;
Milani, Andrea ;
Bologna, Alessandra ;
Blasi, Livio ;
De Placido, Sabino ;
Diodati, Lucrezia ;
Beano, Alessandra ;
Romagnoli, Emanuela ;
Cazzaniga, Marina Elena .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[15]   Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly-Preliminary results of the GIM-13 AMBRA study. [J].
Mustacchi, Giorgio ;
Pronzato, Paolo ;
D'Alonzo, Alessia ;
Mocerino, Carmela ;
Romagnoli, Emanuela ;
Garrone, Ornella ;
Blasi, Livio ;
De Laurentiis, Michelino ;
Michelotti, Andrea ;
Bologna, Alessandra ;
Giordano, Monica ;
Turletti, Anna ;
Montemurro, Filippo ;
De Placido, Sabino ;
Natoli, Clara ;
Taverniti, Cristiana ;
Biganzoli, Laura ;
Meattini, Icro ;
Marchetti, Paolo ;
Cazzaniga, Marina Elena .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[16]   Triple negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study [J].
Mustacchi, Giorgio ;
Beano, Alessandra ;
Fabi, Alessandra ;
Livi, Lorenzo ;
Bernardo, Antonio ;
Riccardi, Ferdinando ;
Marchetti, Paolo ;
Garrone, Ornella ;
Diodati, Lucrezia ;
Biganzoli, Laura ;
Giordano, Monica ;
Turletti, Anna ;
Blasi, Livio ;
Milani, Andrea ;
Natoli, Clara ;
Riemma, Marta ;
D'Alonzo, Alessia ;
Arpino, Grazia ;
Pronzato, Paolo ;
Cazzaniga, Marina E. .
CANCER RESEARCH, 2020, 80 (04)
[17]   Therapeutic impact of novel agents in patients with stage IV de novo HR+ve/Her2-ve breast cancer: Results from a real world dataset. [J].
Dawood, Shaheenah S. ;
Hernandez, Gema ;
Segovia, Alba .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :1085-1085
[18]   Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study. [J].
Cazzaniga, Marina Elena ;
Pronzato, Paolo ;
Schettini, Francesco ;
Del Mastro, Lucia ;
Riemma, Maria ;
Alu, Massimiliano ;
Turletti, Anna ;
Giordano, Monica ;
Pugliese, Palma ;
De Angelis, Claudia ;
Garrone, Ornella ;
Marchetti, Paolo ;
Riccardi, Ferdinando ;
Bernardo, Antonio ;
Livi, Lorenzo ;
Fabi, Alessandra ;
Taverniti, Cristiana ;
De Placido, Sabino ;
Mustacchi, Giorgio .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[19]   Efficacy of endocrine-versus chemotherapy-based treatments in hormone receptor-positive (HR+ve), HER2-negative (HER2-ve) postmenopausal metastatic breast cancer (mBC): A network meta-analysis (NMA) [J].
Schettini, F. ;
Giuliano, M. ;
Rognoni, C. ;
De Placido, S. ;
Arpino, G. ;
Milani, M. ;
Giordano, A. ;
Cristofanilli, M. ;
Jerusalem, G. ;
Bachelot, T. ;
Pistilli, B. ;
De laurentiis, M. ;
Venturini, S. ;
Generali, D. .
CANCER RESEARCH, 2019, 79 (04)
[20]   A retrospective, multicentric, observational, real-world evidence (RWE) study on cost impact, efficacy, and safety of generic palbociclib in HR+ve, HER2-ve metastatic breast cancer: An Indian perspective. [J].
Deshmuk, Chetan ;
Doshi, Vipul ;
Pathan, Asma ;
Saju, S. V. ;
Rathnam, Krishnakumar ;
Raju, Honey Susan .
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :E13076-E13076
12345